<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829437</url>
  </required_header>
  <id_info>
    <org_study_id>ISG EST</org_study_id>
    <nct_id>NCT02829437</nct_id>
  </id_info>
  <brief_title>Observational Study on Endometrial Stromal Tumors</brief_title>
  <acronym>EST</acronym>
  <official_title>Endometrial Stromal Tumors: an Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Italian Sarcoma Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational, retrospective and prospective study on Endometrial Stromal Tumor (EST)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational, retrospective and prospective study on EST aimed to understand more about its
      biology, natural history and antitumor activity of different treatment options.

      This study will collect data in prospective and retrospective way of patients affected by EST
      and treated according disease guidelines and local practices.

      The study will also review the diagnosis by a central expert pathologist in order to its
      confirmation
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease natural history</measure>
    <time_frame>Through survival, an average of 5 years</time_frame>
    <description>Collection of data on the natural history of endometrial stromal tumors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease diagnosis and classification</measure>
    <time_frame>At the time of diagnosis, an average of 1 month</time_frame>
    <description>Highlight some main issues in pathologic diagnosis of these tumors and their classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy received treatment</measure>
    <time_frame>Through treatment completion, an average of 24 month</time_frame>
    <description>Number and type of chemotherapy agents received for EST treatment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Endometrial Stromal Tumors</condition>
  <arm_group>
    <arm_group_label>Retrospective Observational Group</arm_group_label>
    <description>Patients who received treatment for EST Patients with EST diagnosis prior August 2016</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective Observational Group</arm_group_label>
    <description>Patients who will receive treatment for EST Patients with EST diagnosis after August 2016</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment for EST</intervention_name>
    <description>Surgery and/or Chemotherapy and or/radiotherapy for EST treatment according to disease guidelines: no specific treatment is imposed by protocol (observational study)</description>
    <arm_group_label>Retrospective Observational Group</arm_group_label>
    <arm_group_label>Prospective Observational Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Paraffin-embedded pathologic tissue used for diagnostic confirmation purposes only
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All the patients with a diagnosis of Endometrial Stromal Tumor (EST)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with a diagnosis of Endometrial Stromal Tumor (EST) according to the World
             Health Organization (WHO) classification 2003 or 2014

          -  Informed consent signature

        Exclusion Criteria:

          -  patients with different diagnosis from EST
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo G Casali, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Italian Sarcoma Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emanuela Marchesi, PhD</last_name>
    <phone>+390516366</phone>
    <phone_ext>470</phone_ext>
    <email>emanuela.marchesi@ior.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Toni Ibrahim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo G. Casali, MD</last_name>
      <email>paolo.casali@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Paolo G. Casali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tommaso M. De Pas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Russo, MD</last_name>
      <phone>+39 091 6552534</phone>
      <email>antonio.russo@usa.net</email>
    </contact>
    <investigator>
      <last_name>Antonio Russo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico di Aviano</name>
      <address>
        <city>Aviano</city>
        <state>PD</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Buonadonna, MD</last_name>
      <phone>+390434659190</phone>
      <email>abuonadonna@cro.it</email>
    </contact>
    <investigator>
      <last_name>Angela Buonadonna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonella Brunello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia IRCC Candiolo</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Grignani, MD</last_name>
      <phone>+390119933623</phone>
      <email>enrico.grignani@ircc.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Grignani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Orsola Malpighi - Unit of Medical Oncology</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Abbondanza Pantaleo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Gasperoni, MD</last_name>
      <phone>39 055 7949648</phone>
      <email>gasperoni.silvia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Silvia Gasperoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniela Greto, MD</last_name>
      <phone>+ 39055794</phone>
      <phone_ext>111</phone_ext>
      <email>daniela.greto@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Daniela Greto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Misericordia e Dolce Ist. Toscano Tumori, Az. USL4</name>
      <address>
        <city>Prato</city>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giacomo G Baldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Vincenzi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bruno Vincenzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituti Fisioterapici Ospitalieri di Roma</name>
      <address>
        <city>Roma</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Virginia Ferraresi, MD</last_name>
      <email>virginia.ferraresi@ifo.gov.it</email>
    </contact>
    <investigator>
      <last_name>Virginia Ferraresi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004 Apr;93(1):204-8.</citation>
    <PMID>15047237</PMID>
  </reference>
  <reference>
    <citation>Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer. 2006 Dec 15;119(12):2922-30.</citation>
    <PMID>17013893</PMID>
  </reference>
  <reference>
    <citation>Ali RH, Rouzbahman M. Endometrial stromal tumours revisited: an update based on the 2014 WHO classification. J Clin Pathol. 2015 May;68(5):325-32. doi: 10.1136/jclinpath-2014-202829. Epub 2015 Jan 16. Review.</citation>
    <PMID>25595274</PMID>
  </reference>
  <reference>
    <citation>Tavassoli FA, Norris HJ. Mesenchymal tumours of the uterus. VII. A clinicopathological study of 60 endometrial stromal nodules. Histopathology. 1981 Jan;5(1):1-10.</citation>
    <PMID>7216172</PMID>
  </reference>
  <reference>
    <citation>Dionigi A, Oliva E, Clement PB, Young RH. Endometrial stromal nodules and endometrial stromal tumors with limited infiltration: a clinicopathologic study of 50 cases. Am J Surg Pathol. 2002 May;26(5):567-81.</citation>
    <PMID>11979087</PMID>
  </reference>
  <reference>
    <citation>Su TF, Chao TK, Lee HS, Perng CL, Nieh S. Malignant potential of endometrial stromal tumor with limited infiltration: a case report. Int J Surg Pathol. 2014 Sep;22(6):559-63. doi: 10.1177/1066896913506934. Epub 2013 Oct 23. Erratum in: Int J Surg Pathol. 2015 May;23(3):257.</citation>
    <PMID>24155223</PMID>
  </reference>
  <reference>
    <citation>Dong R, Pang Y, Mao H, Yang N, Liu P. Successful pregnancy following conservative management of low-grade endometrial stromal sarcoma: A case report. Oncol Lett. 2014 Apr;7(4):1039-1042. Epub 2014 Feb 7.</citation>
    <PMID>24944665</PMID>
  </reference>
  <reference>
    <citation>Choi MC, Kim G, Hwang YY. Fertility-sparing management combined with photodynamic therapy for endometrial stromal sarcoma: a case report. Photodiagnosis Photodyn Ther. 2014 Dec;11(4):533-6. doi: 10.1016/j.pdpdt.2014.07.007. Epub 2014 Aug 11.</citation>
    <PMID>25125393</PMID>
  </reference>
  <reference>
    <citation>Della Badia C, Karini H. Endometrial stromal sarcoma diagnosed after uterine morcellation in laparoscopic supracervical hysterectomy. J Minim Invasive Gynecol. 2010 Nov-Dec;17(6):791-3. doi: 10.1016/j.jmig.2010.07.001.</citation>
    <PMID>20955991</PMID>
  </reference>
  <reference>
    <citation>Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. The impact of tumor morcellation during surgery on the outcomes of patients with apparently early low-grade endometrial stromal sarcoma of the uterus. Ann Surg Oncol. 2011 Nov;18(12):3453-61. doi: 10.1245/s10434-011-1751-y. Epub 2011 May 4.</citation>
    <PMID>21541824</PMID>
  </reference>
  <reference>
    <citation>Shah JP, Bryant CS, Kumar S, Ali-Fehmi R, Malone JM Jr, Morris RT. Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol. 2008 Nov;112(5):1102-8. doi: 10.1097/AOG.0b013e31818aa89a.</citation>
    <PMID>18978112</PMID>
  </reference>
  <reference>
    <citation>Dos Santos LA, Garg K, Diaz JP, Soslow RA, Hensley ML, Alektiar KM, Barakat RR, Leitao MM Jr. Incidence of lymph node and adnexal metastasis in endometrial stromal sarcoma. Gynecol Oncol. 2011 May 1;121(2):319-22. doi: 10.1016/j.ygyno.2010.12.363. Epub 2011 Jan 26.</citation>
    <PMID>21276609</PMID>
  </reference>
  <reference>
    <citation>Amant F, De Knijf A, Van Calster B, Leunen K, Neven P, Berteloot P, Vergote I, Van Huffel S, Moerman P. Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. Br J Cancer. 2007 Nov 5;97(9):1194-9. Epub 2007 Sep 25.</citation>
    <PMID>17895898</PMID>
  </reference>
  <reference>
    <citation>Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol. 2009 Dec;10(12):1188-98. doi: 10.1016/S1470-2045(09)70226-8. Review.</citation>
    <PMID>19959075</PMID>
  </reference>
  <reference>
    <citation>Rauh-Hain JA, del Carmen MG. Endometrial stromal sarcoma: a systematic review. Obstet Gynecol. 2013 Sep;122(3):676-83. doi: 10.1097/AOG.0b013e3182a189ac. Review.</citation>
    <PMID>23921879</PMID>
  </reference>
  <reference>
    <citation>Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Urgesi A, Lissoni A, Losa G, Fanucchi A. Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol. 1996 Nov;63(2):247-53.</citation>
    <PMID>8910635</PMID>
  </reference>
  <reference>
    <citation>Chu MC, Mor G, Lim C, Zheng W, Parkash V, Schwartz PE. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol. 2003 Jul;90(1):170-6.</citation>
    <PMID>12821359</PMID>
  </reference>
  <reference>
    <citation>Li AJ, Giuntoli RL 2nd, Drake R, Byun SY, Rojas F, Barbuto D, Klipfel N, Edmonds P, Miller DS, Karlan BY. Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol. 2005 Dec;106(6):1304-8.</citation>
    <PMID>16319256</PMID>
  </reference>
  <reference>
    <citation>Kim WY, Lee JW, Choi CH, Kang H, Kim TJ, Kim BG, Lee JH, Bae DS. Low-grade endometrial stromal sarcoma: a single center's experience with 22 cases. Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1084-9. doi: 10.1111/j.1525-1438.2007.01159.x. Epub 2007 Dec 27.</citation>
    <PMID>18179547</PMID>
  </reference>
  <reference>
    <citation>Altman AD, Nelson GS, Chu P, Nation J, Ghatage P. Uterine sarcoma and aromatase inhibitors: Tom Baker Cancer Centre experience and review of the literature. Int J Gynecol Cancer. 2012 Jul;22(6):1006-12. doi: 10.1097/IGC.0b013e31825b7de8. Review.</citation>
    <PMID>22740004</PMID>
  </reference>
  <reference>
    <citation>Leath CA 3rd, Huh WK, Hyde J Jr, Cohn DE, Resnick KE, Taylor NP, Powell MA, Mutch DG, Bradley WH, Geller MA, Argenta PA, Gold MA. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol. 2007 Jun;105(3):630-4. Epub 2007 Feb 23.</citation>
    <PMID>17320937</PMID>
  </reference>
  <reference>
    <citation>Thomas MB, Keeney GL, Podratz KC, Dowdy SC. Endometrial stromal sarcoma: treatment and patterns of recurrence. Int J Gynecol Cancer. 2009 Feb;19(2):253-6. doi: 10.1111/IGC.0b013e3181999c5f.</citation>
    <PMID>19396004</PMID>
  </reference>
  <reference>
    <citation>Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, Zaino RJ. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983 Aug 15;52(4):626-32.</citation>
    <PMID>6344983</PMID>
  </reference>
  <reference>
    <citation>Cheng X, Yang G, Schmeler KM, Coleman RL, Tu X, Liu J, Kavanagh JJ. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol. 2011 May 1;121(2):323-7. doi: 10.1016/j.ygyno.2010.12.360. Epub 2011 Jan 28.</citation>
    <PMID>21277011</PMID>
  </reference>
  <reference>
    <citation>Piver MS, Rutledge FN, Copeland L, Webster K, Blumenson L, Suh O. Uterine endolymphatic stromal myosis: a collaborative study. Obstet Gynecol. 1984 Aug;64(2):173-8.</citation>
    <PMID>6738952</PMID>
  </reference>
  <reference>
    <citation>Sutton G, Blessing JA, Park R, DiSaia PJ, Rosenshein N. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. Obstet Gynecol. 1996 May;87(5 Pt 1):747-50.</citation>
    <PMID>8677079</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Stromal Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Aggregate anonymized results will be available upon request at the end of the study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

